Mark G Swain (Mark Swain)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 14

Top Topics

Hepatitis C Virus

Top Venues

Hepatology communications

Hepatology (Baltimore, Md.)

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

David E J Jones, Ulrich H W Beuers, Alan Bonder, Marco Carbone, Emma L Culver, Jessica Katharine Dyson, Robert G Gish, Bettina E Hansen, Gideon M Hirschfield, Rebecca Jones, Kris Kowdley, Andreas E Kremer, Keith D Lindor, Marlyn J Mayo, George Mells, James Neuberger, Martin Prince, Mark G Swain, Atsushi Tanaka, Douglas Thorburn, Michael Trauner, Palak J Trivedi, Martin Weltman, Andrew D Yeoman, Cynthia Levy
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here? Hepatology (Baltimore, Md.) (2024)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
Abdel Aziz Shaheen, Gilaad G Kaplan, Keith A Sharkey, Brendan Lethebe, Mark G Swain
Impact of depression and antidepressant use on clinical outcomes of hepatitis B and C: a population-based study. Hepatology communications 7 (3) (2023)
Abdel Aziz Shaheen, Gilaad G Kaplan, Keith A Sharkey, Brendan Lethebe, Mark G Swain
Impact of depression and antidepressant use on clinical outcomes of hepatitis B and C: a population-based study. Hepatology communications 7 (3) (2023)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
Abdel Aziz Shaheen, Gilaad G Kaplan, Keith A Sharkey, Brendan Lethebe, Mark G Swain
Impact of depression and antidepressant use on clinical outcomes of hepatitis B and C: a population-based study. Hepatology communications 7 (3) (2023)
Abdel Aziz Shaheen, Gilaad G Kaplan, Keith A Sharkey, Brendan Lethebe, Mark G Swain
Impact of depression and antidepressant use on clinical outcomes of hepatitis B and C: a population-based study. Hepatology communications 7 (3) (2023)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
Abdel Aziz Shaheen, Gilaad G Kaplan, Keith A Sharkey, Brendan Lethebe, Mark G Swain
Impact of depression and antidepressant use on clinical outcomes of hepatitis B and C: a population-based study. Hepatology communications 7 (3) (2023)
David E J Jones, Marco Carbone, Invernizzi Pietro, Nicola Little, Frederik Nevens, Mark G Swain, Philippe Wiesel, Cynthia Levy
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. Hepatology communications 7 (3) (2023)
Gideon M Hirschfield, Mitchell L Shiffman, Gideon M Hirschfield, Kris V Kowdley, John M Vierling, Cynthia Levy, Andreas E Kremer, Ehud Zigmond, Pietro Andreone, Stuart C Gordon, Christopher L Bowlus, Eric J Lawitz, Richard J Aspinall, Daniel S Pratt, Karina Raikhelson, Maria S Gonzalez-Huezo, Michael A Heneghan, Sook-Hyang Jeong, Alma L Ladrón de Guevara, Marlyn J Mayo, Georgios N Dalekos, Joost Paulus Hubertus Drenth, Ewa Janczewska, Barbara A Leggett, Frederik Nevens, Víctor Vargas, Eli Zuckerman, Christophe Corpechot, Eduardo Fassio, Holger Hinrichsen, Invernizzi Pietro, Palak J Trivedi, Lisa Forman, David E J Jones, Stephen D Ryder, Mark G Swain, Alexandra Steinberg, Pol F Boudes, Yun-Jung Choi, Charles A McWherter, null null
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology (Baltimore, Md.) (2023)
Marlyn J Mayo, John M Vierling, Christopher L Bowlus, Cynthia Levy, Gideon M Hirschfield, Guy W Neff, Michael R Galambos, Stuart C Gordon, Brian B Borg, Stephen A Harrison, Paul J Thuluvath, Aparna Goel, Mitchell L Shiffman, Mark G Swain, David E J Jones, Palak J Trivedi, Andreas E Kremer, Richard J Aspinall, David A Sheridan, Yvonne Dörffel, Ke Yang, Yun-Jung Choi, Charles A McWherter
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Alimentary pharmacology & therapeutics (2023)